When seeking help for a substance use disorder, it is critical to choose a program grounded in science rather than anecdotal success. The phrase “evidence-based addiction treatment” is often used in the behavioral health field, but what does it actually mean? At its core, it means that the therapies, medications, and treatment timelines utilized by a facility have been rigorously tested in clinical trials and peer-reviewed studies, and have consistently demonstrated positive outcomes for patients.
At Discovery Point Retreat, our entire continuum of care is built on the foundation of clinical research. By aligning our treatment protocols with the findings of leading medical institutions, we maximize the chances of long-term recovery for our clients. Below is a detailed look at the 11 primary research sources that inform our approach to addiction medicine.
The National Institute on Drug Abuse (NIDA)
The National Institute on Drug Abuse (NIDA) is the leading federal agency supporting scientific research on drug use and its consequences. Their findings form the backbone of modern addiction treatment.
- This foundational document establishes that addiction is a complex but treatable brain disease. It highlights that no single treatment is appropriate for everyone, and that effective treatment must attend to multiple needs of the individual, not just their drug abuse. Crucially, NIDA research established the “90-day threshold,” demonstrating that treatment outcomes significantly improve when patients remain engaged in care for at least 90 days.
- This report provides the clinical justification for Medication-Assisted Treatment (MAT). It details how medications like buprenorphine, methadone, and naltrexone relieve withdrawal symptoms and psychological cravings, significantly lowering the risk of fatal overdose.
- This comprehensive overview reinforces the necessity of combining behavioral therapy with medical interventions to achieve lasting behavioral change.
The Substance Abuse and Mental Health Services Administration (SAMHSA)
SAMHSA is the agency within the U.S. Department of Health and Human Services that leads public health efforts to advance the behavioral health of the nation.
- This protocol outlines the clinical issues in Intensive Outpatient Treatment (IOP). It provides the evidence base for why step-down care is critical, showing that patients who transition from residential care into IOP have significantly lower relapse rates than those who attempt to return to independent living immediately.
- Focused specifically on medications for opioid use disorder, this protocol provides the clinical guidelines for administering MAT safely and effectively within outpatient and residential settings.
The X:BOT Clinical Trial (Lee et al., 2018)
The Lancet
, the X:BOT (Extended-Release Naltrexone vs. Buprenorphine-Naloxone) trial is one of the most important studies comparing MAT medications.
The study compared the effectiveness of the Vivitrol shot (extended-release naltrexone) against daily Suboxone (buprenorphine-naloxone). The findings revealed that both medications are highly effective at preventing relapse once successfully initiated. However, the study highlighted the clinical challenge of naltrexone induction, as patients must be completely detoxed from opioids before receiving the shot. This data helps clinicians determine which medication is most appropriate based on a patient’s current stage of detox.
Vista Research Group Data
Vista Research Group conducts independent, third-party outcomes research for addiction treatment centers. Their data provides some of the clearest evidence regarding the continuum of care.
According to their outcomes tracking, patients who only complete a 7-to-10-day medical detox have approximately a 15% chance of maintaining long-term sobriety. However, when patients complete the full continuum of care—progressing through detox, residential treatment, partial hospitalization, and intensive outpatient care with MAT—their long-term sobriety rate climbs to 76%. This data is the primary driver behind our strong recommendation for step-down care.
Peer-Reviewed Clinical Studies
In addition to federal guidelines, several specific peer-reviewed studies shape the clinical approach to retention and relapse prevention.
- This study focused on treatment retention. It demonstrated that patients receiving Medication-Assisted Treatment remained engaged in the recovery process nearly three times longer (an average of 438 days) compared to those receiving psychosocial treatment alone (174 days).
- This research examined the effectiveness of intensive outpatient programs (IOP) compared to inpatient care, concluding that IOP is a highly effective step-down measure that maintains the clinical gains achieved during residential treatment.
- This study focused on continuing care research, proving that ongoing, low-intensity support following acute treatment significantly reduces the frequency and severity of relapse.
The Drug Abuse Treatment Outcome Study (DATOS)
DATOS is one of the largest and most comprehensive long-term studies on drug abuse treatment outcomes. The data from DATOS consistently shows that the length of time spent in treatment is one of the most reliable predictors of post-treatment success. It reinforces the NIDA 90-day rule and provides the statistical justification for extended residential and outpatient programs.
HHS ASPE Report on MAT
The Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation (ASPE) produced a definitive report on the impact of MAT. The report concluded that the use of FDA-approved medications for opioid use disorder reduces the risk of relapse during the first year of recovery by approximately 60%. It also noted a significant reduction in the transmission of infectious diseases and criminal justice involvement among MAT patients.
Applying the Evidence at Discovery Point Retreat
Data and research are only valuable if they are actively applied to patient care. At Discovery Point Retreat, we do not guess what might work—we follow the science. By integrating the findings from NIDA, SAMHSA, and leading clinical trials, we provide a continuum of care that is statistically proven to maximize the chances of long-term sobriety.
Frequently Asked Questions
What does evidence-based treatment mean?
Evidence-based treatment refers to medical and psychological interventions that have been rigorously tested in clinical trials and proven effective through peer-reviewed scientific research, rather than relying on unproven or experimental methods.
Is MAT considered evidence-based?
Yes. Medication-Assisted Treatment is widely considered the gold standard of care for opioid use disorder by every major medical and public health organization, including the CDC, NIH, SAMHSA, and the American Medical Association.
Why do treatment centers recommend 90 days of care?
The 90-day recommendation is based directly on clinical research from the National Institute on Drug Abuse (NIDA), which found that treatment lasting fewer than 90 days has limited effectiveness, and that significant brain healing and behavioral changes require extended engagement in care.
If you are looking for an addiction treatment program grounded in science and proven results, contact Discovery Point Retreat today at (855) 245-4127 or visit discoverypointretreat.com/contact-us/ to learn more about our evidence-based approach.
References
[1] NIDA. (2020). Principles of Drug Addiction Treatment: A Research-Based Guide.
[2] Lee, J. D., et al. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT). The Lancet, 391(10118), 309-318.
[3] Timko, C., et al. (2016). Retention in Medication-Assisted Treatment for Opiate Dependence. Journal of Addictive Diseases, 35(1), 22-35.
